Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions

Value in Health

Volumn 16, Issue 5, 2013, Pages 842-847

  Greenberg, Dan ^a,b   Hammerman, Ariel ^c   Vinker, Shlomo ^c   Shani, Adi ^d   Yermiahu, Yuval ^a   Neumann, Peter J ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TUFTS MEDICAL CENTER   (United States)

^c CLALIT HEALTH SERVICES   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

cancer; cost effectiveness; failure; heart; quality of life; willingness to pay

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO ILLNESS; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HUMAN; ISRAEL; MALE; MEDICAL SPECIALIST; METASTASIS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

CANCER; COST-EFFECTIVENESS; HEART FAILURE; QUALITY OF LIFE; WILLINGNESS TO PAY;

ADULT; ATTITUDE OF HEALTH PERSONNEL; COST-BENEFIT ANALYSIS; FEMALE; GENERAL PRACTITIONERS; HEART FAILURE; HUMANS; ISRAEL; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84881660392     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.04.010     Document Type: Article

References (15)

1. P.B. Bach Limits on Medicare's ability to control rising spending on cancer drugs N Engl J Med 360 2009 626 633
2. P.J. Neumann, S.K. Bliss, and J.D. Chambers Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries Health Aff 31 2012 700 708
3. E. Nadler, B. Eckert, and P.J. Neumann Do oncologists believe new cancer drugs offer good value? Oncologist 11 2006 90 95
4. M.A. Kozminski, P.J. Neumann, and E.S. Nadler How long and how well: oncologists' attitudes toward the relative value of life-prolonging vs. quality of life-enhancing treatments Med Decis Making 31 2001 380 385
5. S.R. Berry, C.M. Bell, and P.A. Ubel Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs J Clin Oncol 28 2010 4149 4153
6. P.J. Neumann, J.A. Palmer, and E. Nadler Cancer therapy costs influence treatment: a national survey of oncologists Health Aff 29 2010 196 202
7. P.A. Ubel, S.R. Berry, and E. Nadler In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gain in survival Health Aff 31 2012 709 717
8. D.S. Kazi, and D.B. Mark The economics of heart failure Heart Fail Clin 9 2013 93 106
9. V. Mishra, O. Geiran, and A.E. Fiane Costs and reimbursement gaps after implementation of third-generation left ventricular assist devices J Heart Lung Transplant 29 2010 72 78
10. R. Cookson, C. McCabe, and A. Tsuchiya Public healthcare resource allocation decisions and the rule of rescue J Med Ethics 34 2008 540 544
11. A. Shmueli Survival vs. quality of life: a study of the Israeli public priorities in medical care Soc Sci Med 49 1999 297 302
12. Tamir O, Rabinovich M, Shani M. Year 2006 update of the Israel National List of Health Services. Isr Med Assoc J 2006;8:595-600.
13. D. Greenberg, M.I. Siebzehner, and J.S. Pliskin The process of updating the National List of Health Services in Israel: is it legitimate? Is it fair? Int J Technol Assess Health Care 25 2009 255 261
14. A. Shmueli Economic evaluation of the decisions of the Israeli Public Committee for Updating the National List of Health Services in 2006/2007 Value Health 12 2009 202 206
15. J. Raftery NICE and the challenge of cancer drugs BMJ 338 2009 b67